Listing of Claims

In the claims:

Please cancel claims 1 and 2, without prejudice, and amend claims 3-11 as follows:

- 1. (Canceled)
- 2. (Canceled)
- 3. (Currently Amended) The An anti-inflammatory compound of claim 1, wherein X_b-consists of comprising the following structure:

$$(Y)_{n}X_{a}-X_{1}-X_{2}-X_{3}-X_{4}-X_{5}-X_{6}-(A)_{m}$$

wherein

n and m are each, independently, 0 or 1;

A and Y each comprises from 1 to about 3 amino acid residues;

X_a is a membrane translocation domain comprising from 6 to 15 amino acid residues;

 X_1 is L, A, I or nor-leucine (Nle);

X₂ is D, E, N, Q, homoserine (Hser) or 2-ketopropylalanine (2-ketopropy-A);

X₃ is W, F Y, 4-biphenyl-alanine (Bpa), homophenylalanine (Hphe), 2-

Naphthylalanine (2-Nal), 1-Naphthylalanine (1-Nal), or cycloxexyl-alanine (Cha);

X₄ is S, A, E, L, T, nor-leucine (Nle), or homoserine (Hser);

X₅ is W, H, homophenylalanine (Hphe), 2-Naphthylalanine (2-Nal), 1-

Naphthylalanine (1-Nal), O-benzyl serine (SeroBn), or 3-Pyridylalanine (3-Pal); and

X₆ is L, A, I, or nor-leucine (Nle).

- 4. (Currently Amended) The anti-inflammatory compound of claim ± 3 , wherein n is 1 and Y is the sequence further comprising the amino acid sequence TA.
- 5. (Currently Amended) The anti-inflammatory compound of claim 1 3, wherein m is 1 and A is the sequence further comprising the amino acid sequence QTE.
- 6. (Currently Amended) The anti-inflammatory compound of claim 4 3, wherein X_b-is said compound comprises a sequence selected from the group consisting of TALDWSWLQTE; LDWSWLQTE; TALDWSWL; ALDWSWLQTE; LDWSWLQTE; LDWSWLQT; TALDWSWLQ; ALDWSWLQT; LDWSWLQ; LDWSWLQT; ADWSWL; LDWSWA; ADWSWA; LDFSWL; LDYSWL; LDWAWL; LDWEWL; TAADWSWLQTE; ADWSWLQTE; TAADWSWLQ; AADWSWLQTE; ADWSWLQTE; ADWSWLQT; TAADWSWLQ; AADWSWLQT;

ADWSWLQ; ADWSWLQT; ALDWSWAQTE; LDWSWAQTE; TALDWSWA; ALDWSWAQTE; LDWSWAQTE; LDWSWAQ; TALDWSWAQT; TALDWSWAQ; ALDWSWAQT; LDWSWAQT; LDWSWAQT; TAADWSWAQTE; ADWSWAQTE; ADWSWAQTE; ADWSWAQT; TAADWSWAQT; TAADWSWAQT; TAADWSWAQT; ADWSWAQT; ADWSWAQT; TALDFSWLQTE; LDFSWLQTE; LDFSWLQTE; LDFSWLQTE; LDFSWLQTE; LDFSWLQTE; LDFSWLQTE; LDFSWLQTE; LDYSWLQTE; LDYSWLQTE; LDYSWLQTE; LDYSWLQTE; LDYSWLQTE; LDYSWLQTE; LDYSWLQT; TALDYSWLQT; TALDYSWLQT; TALDYSWLQT; LDYSWLQT; LDYSWLQT; LDWAWLQTE; LDWAWLQTE; LDWAWLQTE; LDWAWLQTE; LDWAWLQTE; LDWAWLQTE; LDWAWLQTE; LDWAWLQTE; LDWAWLQT; LDWAWLQTE; LDWEWLQTE; LDWEWLQTE; LDWEWLQTE; LDWEWLQTE; LDWEWLQTE; LDWEWLQT; ALDWEWLQT; LDWEWLQT; LDWEWLQT;

- 7. (Currently Amended) The anti-inflammatory compound of claim ± 3 , wherein X_a consists of 6-12 amino acid residues.
- 8. (Currently Amended) The anti-inflammatory compound of claim ± 3 , wherein X_a consists of 6-10 amino acid residues.
- 9. (Currently Amended) The anti-inflammatory compound of claim ± 3 , wherein X_a comprises at least five basic amino acid residues.
- 10. (Currently Amended) The anti-inflammatory compound of claim $\frac{1}{2}$, wherein X_a comprises at least five amino acid residues independently selected from L-arginine, D-arginine, L-lysine and D-lysine.
- 12. (Original) An anti-inflammatory compound comprising an amino acid sequence selected from the group consisting of: RRMKWKKTALDWSWLQTE; rrmkwkkTALDWSWLQTE; YGRKKRRQRRRTALDWSWLQTE; ygrkkrrqrrrTALDWSWLQTE; rrrrrrTALDWSWLQTE; RRRRRRRTALDWSWLQTE; YARKARRQARRTALDWSWLQTE; yarkarrqarrTALDWSWLQTE YARAARRAARRTALDWSWLQTE; yaraarraarrTALDWSWLQTE

YGRKKRRQRRRLDWSWL; ygrkkrrqrrrLDWSWL; RRMKWKKLDWSWL; rrmkwkkLDWSWL; rrrrrrLDWSWL; YARAARRAARRLDWSWL; yaraarraarrLDWSWL; and RRRRRRLDWSWL.

13. (**Original**) An anti-inflammatory compound having a structure selected from the group consisting of:

H-RRMKWKKTALDWSWLQTE-NH₂;

H-YGRKKRRQRRRTALDWSWLQTE-NH2;

H-rrrrrrTALDWSWLQTE-NH₂;

H-YARKARRQARRTALDWSWLQTE-NH₂;

H-YARAARRAARRTALDWSWLQTE-NH2;

H-RRMKWKKLDWSWL-NH₂;

H-rrmkwkkLDWSWL-NH₂;

H-rrrrrrLDWSWL-NH₂;

H-YARAARRAARRLDWSWL-NH₂;

H-yaraarraarrLDWSWL-NH2; and

H-YGRKKRRQRRRLDWSWL-NH₂.